The #FDA has extended its review of #Novo's experimental #haemophiliaA drug #denecimig because of ongoing remediation work at a facility that will be used to manufacture the #FactorVIIIamimetic.
Explore
Novo's Denecimig Shows Promise as a Tolerable Treatment for Hemophilia A in Recent Study #None #Novo_Nordisk #Hemophilia_A #Denecimig
